Trial Profile
A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors Abbott Biotherapeutics Corp; Abbott Laboratories; AbbVie
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 24 Oct 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Nov 2016.